Company Overview and News
SQ Advisors has just fifteen positions. The top three holdings are Allison Transmission, Brookfield Asset Management, and Charles Schwab, and they add up to one-third of the entire portfolio.
Warren Buffett's Berkshire Hathaway Inc on Tuesday said it has more than doubled its investment in generic drugmaker Teva Pharmaceutical Industries Ltd , and confirmed it has become Apple Inc's second-largest shareholder.
This article is part of a series that provides an ongoing analysis of the changes made to Berkshire Hathaway’s (NYSE:BRK.A) (NYSE:BRK.B) 13F stock portfolio on a quarterly basis. It is based on Warren Buffett’s regulatory 13F Form filed on 05/15/2018. Please visit our Tracking 10 Years Of Berkshire Hathaway's Investment Portfolio article series for an idea on how his holdings have progressed over the years and our previous update for the moves in Q4 2017.
While a recession is not in our forecast in the near term, the credit cycle is in its final innings.
This copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to your colleagues, clients or customers visit http://www.djreprints.com.
Good morning, ladies and gentlemen, and welcome to the WOW First Quarter 2018 Earnings Call. As a reminder, I want to advise everyone that this call is being recorded. At this time, I would like to turn the call over to Mr. Lucas Binder, WOW!'s Vice President, Corporate Development and Investor Relations. Please go ahead, Mr. Binder.
The U.S. Senate will vote in the coming week as a last ditch attempt to save the Net Neutrality laws which were repealed by the Federal Communications Commission (FCC) on Dec 14, 2017. The newly constructed FCC under Trump administration with Ajit Pai at the helm repealed the Obama-era rules which altered the dynamics of the Internet Service Providers (ISP) industry. Senate Democrats are hopeful to win the vote regarding the restoration of Net Neutrality.
Smith Micro Software, Inc. (NASDAQ:SMSI) Q1 2018 Earnings Conference Call May 9, 2018 4:30 PM ET
This was the case when T-Mobile (NASDAQ:TMUS) CEO John Legere and Sprint (NYSE:S) CEO Marcelo Claure popped up on live TV promoting affordability, elevated competition, and massive 5G infrastructure investments if the two companies joined forces in a $26.5 billion deal.
AURORA, Ill., May 09, 2018 (GLOBE NEWSWIRE) -- Westell Technologies, Inc. (NASDAQ:WSTL), a leading provider of high-performance wireless infrastructure solutions, today announced that its Board of Directors has chosen Alfred S. (Stephen) John as the Company’s new President and CEO, effective May 21, 2018. Stephen succeeds interim President and CEO Kirk Brannock, who will retain the role of Chairman of the Board of Directors.
Comcast Corporation (NASDAQ:CMCSA) reported great earnings last week. The stock market rewarded Comcast stock by dropping it to new 52-week lows. Now Mr. Market doesn’t always react to news how you’d expect. Even still, this is a pretty unusual reaction.
WASHINGTON (Reuters) - In its final push, the U.S. Justice Department has urged a federal judge to stop AT&T Inc (T.N), which owns biggest pay TV provider DirecTV, from buying movie and TV show maker Time Warner Inc (TWX.N), or at least cut a big chunk out of the proposed $85 billion transaction.
In its final push, the U.S. Justice Department has urged a federal judge to stop AT&T Inc , which owns biggest pay TV provider DirecTV, from buying movie and TV show maker Time Warner Inc , or at least cut a big chunk out of the proposed US$85 billion transaction.
Despite knee jerk volatility, Roku will become a large cap stock in OTT (over-the-top) within 2-5 years.
I have invested in Liberty Media (NASDAQ:FWONA) (OTCQB:FWONB) for over 20 years and owned each of the different entities in the complex and now is an interesting time to look at the various entities. Before investigating some of the possibilities, it is important to note that the chairman of Liberty John Malone has a Ph.D. in operations management from John Hopkins. Most investors are familiar with Mr.
7h - Asif
Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...
8h - Asif
BUSINESS TrovaGene is a clinical-stage, precision medicine oncology therapeutics company. The company's primary focus is to develop oncology therapeutics for improved cancer care and to optimize drug development by leveraging its proprietary Precision Cancer Monitoring® (“PCM”) technology in tumor genomics. The company's lead drug candidate, PCM-075, is a Polo-like Kinase 1 (“PLK1”) selective adenosine triphosphate (“ATP”) competitive inhibitor. PCM-075 has shown preclinical antitumor activity as a single agent and synergy in combination with more than ten different chemotherapeutics and targeted therapies, such as Zytiga® (abiraterone acetate), Beleodaq® (belinostat), Quizartinib (AC220), a development stage FLT3 inhibitor, and Velcade® (bortezomib) in Acute Myeloid Leukemia (“AML”), metastatic Castration-Resistant Prostate Cancer (“mCRPC”) and other hematologic and solid tumor cancers. On March 15, 2017, the company announced the licensing of PCM-075, a PLK1 inhibitor...
2018-05-19 - Asif
OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...
as of ET